ClinicalTrials.gg
CompletedNCT04572854NOBLEUpdated Apr 21, 2026Results posted

Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

A Phase 2 interventional study of Pegcetacoplan in C3G, IC-MPGN and Renal Transplant, sponsored by Apellis Pharmaceuticals, Inc.. Completed at 25 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States — 1 open to participants now, 2 under way, 2 of them phase 3. Glomerulonephritis, Membranoproliferative · United States.

Enrollment
8th of 15
13 · median 13
Started
2021
with 1 other
Phase 2
7 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
4 of 15
Apellis Pharmaceuticals, Inc.

Among the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, this one is the 8th largest by enrollment, is one of 2 that started in 2021, is one of 7 in phase 2, and was the 13th registered.

Glomerulonephritis, Membranoproliferative

33 studies on the registry are indexed under Glomerulonephritis, Membranoproliferative; 10 are open to participants now.

Browse Glomerulonephritis, Membranoproliferative studies →

Open to participants now

1 of the 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Glomerulonephritis, Membranoproliferative studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Glomerulonephritis, Membranoproliferative with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G or IC-MPGN.

03

Conditions studied

  • C3G
  • IC-MPGN
  • Renal Transplant
  • Complement 3 Glomerulopathy
  • Complement 3 Glomerulopathy (C3G)
  • Dense Deposit Disease (DDD)
  • Membranoproliferative Glomerulonephritis
  • Membranoproliferative Glomerulonephritis (MPGN)
  • Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
  • C3 Glomerulopathy
  • C3 Glomerulonephritis
  • Complement 3 Glomerulonephritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age at screening
  • Must have clinical and pathologic evidence of recurrent C3G or IC-MPGN
  • Stable (not improving) or worsening disease, in the opinion of the investigator, in the 2 months preceding the first dose of pegcetacoplan
  • ≥15 mL/min/1.73 m2, calculated by the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation for adults
  • No more than 50% glomerulosclerosis or interstitial fibrosis on the screening renal allograft
  • Stable regimen for recurrent C3G/IC-MPGN for at least 4 weeks prior to the screening renal allograft biopsy and from the time of the screening renal allograft biopsy until randomization
  • Have received required vaccinations against N. meningitidis, S. pneumoniae, and H. influenzae (type B) or agree to receive vaccinations, if applicable vaccination records are not available. Vaccination is mandatory unless documented evidence exists that subjects are non-responders to vaccination.

Exclusion criteria

Exclusion Criteria:

  • \<1000 cells/mm3 during screening
  • Previous treatment with pegcetacoplan
  • Evidence of rejection on the screening renal allograft that requires treatment
  • Diagnosis or history of , , or infection or positive serology at screening indicative of infection with any of these viruses
  • Weight more than 100 kg at screening
  • to pegcetacoplan or any of the
  • History of meningococcal disease
  • , except for the following:
  • Cured basal or squamous cell skin cancer
  • Curatively treated in situ disease
  • Malignancy free and off treatment for ≥5 years
  • Significant renal disease in the renal allograft secondary to another condition (eg, infection, malignancy, monoclonal gammopathy, rejection, or a medication) that would, in the opinion of the investigator, confound interpretation of the study results
  • Participation in any other drug trial or exposure to other investigational agent, device, or procedure within 30 days or 5 half-lives from the last dose of the investigational agent (whichever is longer) prior to screening
  • Known or suspected hereditary fructose intolerance.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Group 1

    Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.

    Drug: Pegcetacoplan

  • Other
    Group 2

    No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.

    Drug: Pegcetacoplan

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12

    C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 12

Secondary outcomes

  1. Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 52

    C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  2. Number of Subjects With Shift of C3c Staining From Baseline to Weeks 12 and 52

    C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects. Number of subjects who demonstrated a shift of C3c staining from baseline to Week 12 and baseline to Week 52 are presented.

    Time frame: Baseline (Day 1), Week 12 and Week 52

  3. Percentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 52

    eGFR was calculated by using Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation. Stabilization or improvement in eGFR was defined as no more than a 25% decrease relative to baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  4. Percentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 52

    Stabilization or improvement in serum creatinine was defined as no increase or an increase of no more than 25% from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  5. Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52

    Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  6. Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52

    Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  7. Change From Baseline in Serum Creatinine Concentration at Week 52

    Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

  8. Percentage Change From Baseline in Serum Creatinine Concentration at Week 52

    Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

    Time frame: Baseline (Day 1) and Week 52

07

Results

Posted Feb 7, 2025

Participant flow

This phase 2, open-label study was conducted in subjects with post-transplant recurrence of complement 3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN) at 23 sites across 11 countries. First subject was recruited on 07 September 2021 and data cut-off (DCO) date was 19 January 2024.

Part A: Controlled: Weeks 1 to 12
Participant flow — Part A: Controlled: Weeks 1 to 12
MilestonePart A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Part A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Started10300
Completed10300
Not completed0000
Part A: Non-controlled: Weeks 13 to 52
Participant flow — Part A: Non-controlled: Weeks 13 to 52
MilestonePart A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Part A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Started00103
Completed0082
Not completed0021
Withdrew: Adverse event0011
Withdrew: Physician decision0010

Outcome measures

PrimaryPercentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12

C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 12
Percentage of participantsPart A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 1250.0 (18.7 to 81.3)33.3 (0.8 to 90.6)
SecondaryPercentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 52

C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Reduction in C3c staining was defined as decrease of at least 2 orders of magnitude of intensity from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Number · Percentage of participants
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 52
Percentage of participantsPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Percentage of Subjects With Reduction in C3c Staining on Renal Biopsy at Week 5250.0 (18.7 to 81.3)66.7 (9.4 to 99.2)
SecondaryNumber of Subjects With Shift of C3c Staining From Baseline to Weeks 12 and 52

C3c staining intensity is semi quantitatively graded on a scale of 0 to 3, in which negative, 1+, 2+ and 3+ staining corresponds to scores of 0 to 3, with 0 being absent and 3 being the highest intensity seen on immunofluorescence. Higher scores indicate worse outcome. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects. Number of subjects who demonstrated a shift of C3c staining from baseline to Week 12 and baseline to Week 52 are presented.

Time frame:
Baseline (Day 1), Week 12 and Week 52
Reported as:
Count of participants · Participants
Number of Subjects With Shift of C3c Staining From Baseline to Weeks 12 and 52
ParticipantsPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Shift from 3 at baseline to 0 at Week 1230
Shift from 2 at baseline to 0 at Week 1210
Shift from 3 at baseline to 1 at Week 1211
Shift from 2 at baseline to 3 at Week 1201
Shift from 3 at baseline to 0 at Week 5241
Shift from 2 at baseline to 0 at Week 5201
Shift from 3 at baseline to 1 at Week 5210
Shift from 2 at baseline to 3 at Week 5210
SecondaryPercentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 52

eGFR was calculated by using Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation. Stabilization or improvement in eGFR was defined as no more than a 25% decrease relative to baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Number · Percentage of participants
Percentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 52
Percentage of participantsPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Percentage of Subjects With Stabilization or Improvement in Estimated Glomerular Filtration Rate (eGFR) at Week 5270.066.7
SecondaryPercentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 52

Stabilization or improvement in serum creatinine was defined as no increase or an increase of no more than 25% from baseline. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Number · Percentage of participants
Percentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 52
Percentage of participantsPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Percentage of Subjects With Stabilization or Improvement of Serum Creatinine Concentration at Week 5270.066.7
SecondaryChange From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52

Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Mean · milliliter/minute/1.73 square meter
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52
milliliter/minute/1.73 square meterPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 5210.1 ± 32.67-10.3 ± 14.57
SecondaryPercentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52

Blood samples were collected at specified timepoints for analysis of eGFR which was calculated by using CKD-EPI creatinine equation. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 52
percentage changePart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Percentage Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 5229.65 ± 78.707-16.67 ± 21.481
SecondaryChange From Baseline in Serum Creatinine Concentration at Week 52

Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Mean · milligram per deciliter
Change From Baseline in Serum Creatinine Concentration at Week 52
milligram per deciliterPart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Change From Baseline in Serum Creatinine Concentration at Week 52-0.044 ± 0.83680.267 ± 0.4619
SecondaryPercentage Change From Baseline in Serum Creatinine Concentration at Week 52

Blood samples were collected at specified timepoints for analysis of serum creatinine concentration. Baseline was defined as the most recent non-missing measurement prior to first administration of study drug for Group 1 subjects or randomization for Group 2 subjects.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in Serum Creatinine Concentration at Week 52
percentage changePart A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Percentage Change From Baseline in Serum Creatinine Concentration at Week 523.198 ± 59.591617.778 ± 30.7920

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and Treatment-emergent serious adverse events (TESAEs) were collected from first dose of study drug for Group 1 subjects or randomization for Group 2 subjects (Day 1) up to 56 days after the last dose of study drug, approximately 139 days for controlled and 333 days for non-controlled portion. All-cause mortality (deaths) were collected from first dose of study drug (Day 1) up to DCO of 19 January 2024, approximately 864 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: Controlled Portion: Group 10/10 (0%)5/10 (50%)7/10 (70%)
Part A: Controlled Portion: Group 20/3 (0%)0/3 (0%)3/3 (100%)
Part A: Non-controlled Portion: Group 10/10 (0%)5/10 (50%)8/10 (80%)
Part A: Non-controlled Portion: Group 20/3 (0%)0/3 (0%)3/3 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPart A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Part A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
Acute kidney injuryRenal and urinary disorders1/100/32/100/3
Nephropathy toxicRenal and urinary disorders1/100/31/100/3
Renal tubular disorderRenal and urinary disorders1/100/30/100/3
Urinary tract obstructionRenal and urinary disorders0/100/31/100/3
Arthritis bacterialInfections and infestations0/100/31/100/3
Genital herpes simplexInfections and infestations1/100/31/100/3
Pneumocystis jirovecii infectionInfections and infestations0/100/31/100/3
PneumoniaInfections and infestations0/100/31/100/3
NeutropeniaBlood and lymphatic system disorders1/100/30/100/3
Cardiac failureCardiac disorders0/100/31/100/3
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPart A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Part A: Non-controlled Portion: Group 1Part A: Non-controlled Portion: Group 2
COVID-19Infections and infestations2/101/31/100/3
InfluenzaInfections and infestations1/101/30/100/3
Tinea versicolourInfections and infestations0/101/30/100/3
NasopharyngitisInfections and infestations0/100/31/101/3
Herpes zosterInfections and infestations0/100/30/101/3
DiarrhoeaGastrointestinal disorders1/101/30/101/3
NauseaGastrointestinal disorders1/100/30/101/3
Rectal haemorrhageGastrointestinal disorders0/100/30/101/3
AnaemiaBlood and lymphatic system disorders1/101/31/101/3
Weight decreasedInvestigations1/101/30/100/3

Baseline characteristics

The intent-to-treat (ITT) population included all subjects who were randomized.

Age, Continuous
Age, Continuous(Years)Part A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Total
Mean39.8 ± 12.5944.3 ± 24.0340.8 ± 14.80
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Total
Female516
Male527
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Total
White9312
Not reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: Controlled Portion: Group 1Part A: Controlled Portion: Group 2Total
Hispanic or Latino112
Not Hispanic or Latino9211
08

Study locations

25 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Keck School of Medicine, University of Southern California
    Los Angeles, California 900033, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Washington University, St.Louis
    St Louis, Missouri 63110, United States
  • NYU Langone Health Transplant Insitute
    New York, New York 10016, United States
  • CUIMC
    New York, New York 10032, United States
  • Hospital de Alta Complejidad en Red El Cruce Dr. Nestor Carlos Kirchner
    San Juan Bautista, Buenos Aires B1888AAE, Argentina
  • Hospital Universitario Fundacion Favaloro
    Buenos Aires, C1093AAS, Argentina
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • Monash Medical Centre
    Clayton, 3168, Australia
  • Medical University of Vienna
    Vienna, 1090, Austria
  • Irmandade da Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP
    Botucatu, São Paulo 18618-686, Brazil
  • Santa Casa de Misericordia de Belo Horizonte
    Belo Horizonte, CEP 30150-221, Brazil
  • Clinical Research Center, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, 05403-000, Brazil
  • Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology
    Lille, 59000, France
  • Hopital Edouard Herriot, Hospices Civils de Lyon
    Lyon, 69437, France
  • Center Hospitalier Universitaire de Montpellier
    Montpellier, 34295 CEDEX 5, France
  • Istituto di Ricerche Farmacologiche Mario Negri IRCCS
    Ranica, 24020, Italy
  • Radbound University Medical Center
    Nijmegen, 6500 HB, Netherlands
  • Hospital Universitario 12 de Octubre, Nephrology Department
    Madrid, 28041, Spain
  • CHUV
    Lausanne, 1005, Switzerland
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Feb 2023, 17 months.

Results were first posted in Feb 2025, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2020
First posted
Oct 1, 2020
StartActual
Sep 7, 2021
Primary completionActual
Feb 27, 2023
CompletionActual
Jan 20, 2026
Results first posted
Feb 7, 2025
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04572854
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Sep 7, 2021
Primary completion
Feb 27, 2023
Completion
Jan 20, 2026
Results posted
Feb 7, 2025
Last update
Apr 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion